Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a price target of $60.

August 24, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apellis Pharmaceuticals has received a reiterated 'Buy' rating from Needham analyst Joseph Stringer, with a maintained price target of $60.
The reiterated 'Buy' rating and maintained price target by Needham analyst Joseph Stringer indicates a positive outlook for Apellis Pharmaceuticals. This could potentially lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100